An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea

PHASE3CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

November 25, 2019

Primary Completion Date

March 8, 2021

Study Completion Date

January 7, 2022

Conditions
Psoriasis
Interventions
DRUG

BMS-986165

Specified dose on Specified Days

OTHER

Placebo

Specified dose on Specified days

Trial Locations (34)

10002

Local Institution - 0031, Taipei

10380

Local Institution - 0033, Goyang-si

11490

Local Institution - 0032, Taipei

13496

Local Institution - 0022, Seongnam-si

13620

Local Institution - 0037, Seongnam-si

14584

Local Institution - 0034, Bucheon-si

16499

Local Institution - 0023, Suwon

21565

Local Institution - 0035, Incheon

33305

Local Institution - 0025, Taoyuan District

61469

Local Institution - 0028, Gwangju

83301

Local Institution - 0029, Kaohsiung City

100044

Local Institution - 0001, Beijing

100050

Local Institution - 0007, Beijing

100069

Local Institution - 0014, Beijing

116011

Local Institution - 0006, Dalian

130021

Local Institution - 0002, Changchun

200443

Local Institution - 0012, Jingan

210029

Local Institution, Nanjing

310003

Local Institution - 0009, Hangzhou

310014

Local Institution - 0003, Hangzhou

310016

Local Institution - 0004, Hangzhou

410011

Local Institution, Changsha

430022

Local Institution - 0011, Wuhan

430030

Local Institution - 0016, Wuhan

610041

Local Institution, Chengdu

630014

Local Institution - 0008, Chongqing

030001

Local Institution - 0018, Taiyuan

02447

Local Institution - 0036, Seoul

03080

Local Institution - 0026, Seoul

03722

Local Institution, Seoul

05030

Local Institution - 0021, Seoul

06973

Local Institution - 0020, Seoul

08308

Local Institution - 0027, Seoul

137-701

Local Institution - 0024, Seoul

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY